EWING, N.J., Dec. 18, 2014 /PRNewswire/ -- Celator Pharmaceuticals, Inc. (Nasdaq: CPXX), a biopharmaceutical company transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced that the application of European patent number 2,222,278 was allowed by the European Patent Office. The new patent, "Improved Taxane Delivery System," covers the Company's proprietary taxane prodrug nanoparticle delivery technology and CPX-8, a hydrophobic docetaxel prodrug nanoparticle, which is based on this innovative approach to drug delivery. Celator is currently applying its proprietary CombiPlex technology to drug combinations incorporating targeted agents, such as a combination of docetaxel with a heat shock protein (Hsp90) inhibitor where extended and simultaneous exposure of the two agents to solid tumors at the optimized drug ratio is expected to significantly enhance the efficacy of this combination. This should help establish the broad applicability of the CombiPlex platform in the development of combination cancer therapies. This patent provides protection until November 2028.
Celator's nanoparticle-based delivery technology provides versatile control of the pharmacokinetics and tissue accumulation of taxanes such as paclitaxel and docetaxel. The patent covers a pharmaceutical composition comprising nanoparticles or micelles, where the nanoparticles or micelles are formed from associating (i) a conjugate of taxane coupled to a hydrophobic lipid-anchor through a diglycolate linker with (ii) a lipid and/or amphiphilic stabilizer. The allowed claims may also provide patent protection for formulations combining docetaxel, and other taxanes, with molecularly targeted agents.
"By connecting a hydrophobic anchor to taxanes in a manner that readily incorporates them into stable nanoparticles, we have been able to reduce early distribution of these drugs to healthy tissues while enhancing and extending their exposure to tumor tissue," said Dr. Lawrence Mayer, President and Chief Scientific Officer of Celator. "The improved tumor drug exposure properties correlated with increased anti-tumor activity when compared with conventional formulations of docetaxel at equivalent doses and the reduced toxicity of the nanoparticle formulation in mice led to marked efficacy improvements when it was dosed at the maximum tolerated dose."
About Celator Pharmaceuticals, Inc.
Celator Pharmaceuticals, Inc., with locations in Ewing, N.J., and Vancouver, B.C., is a clinical stage biopharmaceutical company transforming the science of combination therapy, and developing products to improve patient outcomes in cancer. Celator's proprietary technology platform, CombiPlex®, enables the rational design and rapid evaluation of optimized combinations incorporating traditional chemotherapies as well as molecularly targeted agents to deliver enhanced anti-cancer activity. CombiPlex addresses several fundamental shortcomings of conventional combination regimens, as well as the challenges inherent in combination drug development, by identifying the most effective synergistic molar ratio of the drugs being combined in vitro, and fixing this ratio in a nano-scale drug delivery complex to maintain the optimized combination until exposure to the tumor following administration. Celator's pipeline includes lead product, CPX-351 (a liposomal formulation of cytarabine:daunorubicin) for the treatment of acute myeloid leukemia; CPX-1 (a liposomal formulation of irinotecan:floxuridine) for the treatment of colorectal cancer; a preclinical stage product candidate, CPX-8 (a hydrophobic docetaxel prodrug nanoparticle formulation), being studied by the National Cancer Institute's Nanotechnology Characterization Laboratory; and several programs exploring novel combinations of existing drugs, including molecularly targeted therapies.
To the extent that statements contained in this press release are not descriptions of historical facts regarding Celator, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "anticipate," "believe," "estimate," "intend," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Examples of forward-looking statements contained in this press release include, among others, statements regarding the safety, efficacy and therapeutic potential of CPX-351, our expectations regarding the scope and duration of patent protection, our expectations regarding our research and development programs, and expanding our pipeline and advancing our CombiPlex platform. Forward-looking statements in this release involve substantial risks and uncertainties that could cause our preclinical and clinical development programs and other future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the conduct of ongoing and future clinical studies and other matters that could affect the commercial potential of our drug candidates. Celator undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the company in general, see Celator's Form 10-K for the year ended December 31, 2013 and other filings by the company with the U.S. Securities and Exchange Commission.
Media: Mike Beyer Sam Brown, Inc. 773-463-4211 firstname.lastname@example.org
Investors: Adam Krop The Trout Group 646-378-2963 email@example.com
SOURCE Celator Pharmaceuticals, Inc.